Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis

GM Yousef1,2, CA Borgono1,2, A Scorilas3, R Ponzone4, N Biglia4, L Iskander2, M-E Polymeris2, R Roagna4, P Sismondi1 and EP Diamandis*1,2

1Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada; 2Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; 3National Center of Scientific Research ‘Demokritos’, IPC, Athens, 153 10, Greece; 4Academic Division of Gynecological Oncology, University of Turin, Mauriziano Umberto Hospital and Institute for Cancer Research and Treatment (IRCC) of Candolo, Turin, Italy

KLK14 (formerly known as KLK-L6) is a recently identified member of the human kallikrein gene family. This family harbours several genes aberrantly expressed in various cancers as well as established (PSA/hK3, hK2) and potential (hK6, hK10) cancer markers. Similar to other kallikrein genes, KLK14 was found to be regulated by steroid hormones, particularly androgens and progesterins, in breast and ovarian cancer cell lines. Preliminary studies indicated that KLK14 is differentially expressed in breast, ovarian, prostatic and testicular tumours. Given the above, we determined the prognostic significance of KLK14 expression in breast cancer. We studied KLK14 expression in 178 histologically confirmed epithelial breast carcinomas by quantitative reverse transcription–polymerase chain reaction and correlated with clinicopathological variables (tumour stage, grade, histotype etc.) and with outcome (disease-free survival and overall survival), monitored over a median of 76 months. KLK14 mRNA levels ranged from 0 to 1219 arbitrary units in breast cancer tissues, with a mean±s.e. of 136±22. An optimal cutoff value of 40.5 arbitrary units was selected, to categorise tumours as KLK14-positive or negative. Higher concentrations of KLK14 mRNA were more frequently found in patients with advanced stage (III) disease (P=0.032). No statistically significant association was found between KLK14 and the other clinicopathological variables. KLK14 overexpression was found to be a significant predictor of decreased disease-free survival (hazard ratio of 2.31, P=0.001) and overall survival (hazard ratio of 2.21, P=0.005). Cox multivariate analysis indicated that KLK14 was an independent prognostic indicator of disease-free survival and overall survival. KLK14 also has independent prognostic value in subgroups of patients with a tumour size ≤2 cm and positive nodal, oestrogen receptor and progesterin receptor status. We conclude that KLK14 expression, as assessed by quantitative reverse transcription–polymerase chain reaction, is an independent marker of unfavourable prognosis for breast cancer.

British Journal of Cancer (2002) 87, 1287–1293. doi:10.1038/sj.bjc.6600623 www.bjcancer.com © 2002 Cancer Research UK

Keywords: serine proteases; breast cancer; cancer genes; tumour markers; prognostic; predictive factors; kallikreins; KLK14

Breast cancer is the most prevalent malignancy among women, accounting for 21% of all female cancers and ranking third overall when both sexes are considered (Parkin et al, 1999). Although the increased use of screening for early disease diagnosis and the widespread administration of systemic adjuvant therapies have lead to a decline in mortality rates, breast cancer is still the leading cause of death from cancer in women, causing over 39 500 deaths in the US annually (Peto et al, 2000; Jemal et al, 2002).

Given the heterogeneous nature of breast carcinomas, much attention has been focussed on the identification of tumour associated molecular markers that reveal the biological profile of each tumour and ultimately aid in determining cancer risk, diagnosis, screening, prognosis, monitoring, management and prediction of therapeutic response in breast cancer patients (Duffy, 2001).

Among the multitude of markers discovered are serine proteases, which participate in many aspects of carcinogenesis, including stimulating cellular growth, angiogenesis and the degradation of the extracellular matrix (Gottesman, 1990; Duffy, 1991). These functions are in accord with clinical studies demonstrating that the aberrant expression of certain serine proteases correlates with the invasiveness and metastasis of cancer cells and predicts poor prognosis in various malignancies (Herszenyi et al, 1999; Kuhn et al, 1999).

Human kallikreins are a subset of secreted serine proteases found in a wide range of tissues and biological fluids and implicated in diverse physiological and pathological processes (Diamandis et al, 2000b; Yousef and Diamandis, 2001). The kallikrein genes, denoted KLK1–KLK15, are located on chromosome 19q13.4 and encode for corresponding kallikrein enzymes, hK1–hK15 (Diamandis et al, 2000a; Yousef et al, 2000b). Accumulating evidence indicates that many members of this family are differentially expressed in certain malignancies, including prostate (Rittenhouse et al, 1998; Magklara et al, 1999; Barry, 2001; Yousef et al, 2001c; Diamandis et al, 2002), testicular (Luo et al, 2001c), breast (Yousef et al, 2000a,c) and ovarian (Anisowicz et al, 1996; Diamandis et al, 2000c; Kim et al, 2001; Luo et al, 2001b; Magklara et al, 2001; Obiezu et al, 2001; Yousef et al, 2001a) cancers. Also,
many kallikrein genes examined thus far are under steroid hormone regulation, further suggesting a role for these enzymes in endocrine-related tissues (Yousef and Diamandis, 2002). Additionally, PSA/hK3, is the best tumour marker available in clinical medicine for diagnosing and managing prostate cancer (Diamandis, 1998; Barry, 2001), hK2 is useful for certain subgroups of prostate cancer patients (Magklara et al, 1999), hK6, 10 and 11, have recently emerged as potential serological epithelial ovarian cancer markers (Luo et al, 2001a; Diamandis et al, 2002), and several others possess clinical utility as prognostic/predictive markers (Diamandis and Yousef, 2001).

Human kallikrein gene 14 (KLK14), formerly known as KLK-L6, is a recently identified member of the human kallikrein gene family (Yousef et al, 2001b). Structurally, this gene is formed of five coding exons and four intervening introns. The encoded protein, hK14, is a trypsin-like serine protease, translated as an inactive 251 amino acid preproenzyme precursor of about 27.5 kDa, of which 18 amino acids constitute the signal peptide and six amino acids the activation peptide. hK14 harbours the conserved catalytic triad characteristic of serine proteases and is highly homologous to other kallikreins, including PSA/hK3. KLK14 has a restricted tissue expression pattern and is found in the central nervous system as well as in endocrine-related tissues such as the uterus, ovary, thyroid and testis. Additionally, in situ hybridisation studies demonstrated that KLK14 is expressed by the secretory epithelial cells of benign prostate gland, prostatic intraepithelial neoplasia and malignant prostate cells (Hooper et al, 2001). Preliminary studies have shown that KLK14 is down-regulated at the mrNA level in prostatic, testicular, ovarian and breast cancer tissues and in two breast cancer cell lines (Yousef et al, 2001b). Hormonal regulation studies in breast and ovarian cancer cell lines indicate that KLK14 expression is controlled by the androgen receptor in response to steroid horonoes, particularly androgens and progesterins (our unpublished data). Based on these collective findings, we hypothesised that KLK14 expression in malignant breast tissues may have prognostic/predictive value for patients with breast carcinomas.

MATERIALS AND METHODS

Study population

Tumour specimens from 178 consecutive patients undergoing surgical treatment for primary breast carcinoma at the Department of Gynecologic Oncology, University of Turin, Turin, Italy were analysed in this study. Patient age ranged from 25 to 87 years, with a median of 58 years (Table 1). Follow-up information (median follow-up period of 76 months) was available for 164 patients, among whom 60 (36%) had relapsed and 51 (31%) died. All tissue specimens were histologically confirmed and frozen in liquid nitrogen immediately after surgery.

Clinical and pathological information documented at the time of surgery included clinical stage, grade, histology and size of the tumour, number of positive axillary nodes, steroid hormone receptor status and treatment strategy (Table 2). Tumour sizes ranged from 0.1 to 15 cm, with a median of 2.2 cm. Out of the 178 patients, 109 (61%) had ductal carcinoma, 28 (16%) lobular carcinoma while 37 (21%) possessed other histological types. The histotype was unknown for four patients. Patients with disease of all three Stages (I–III) and tumour grades (I–III) were represented in this study, with staging determined according to the TNM classification and grading in accordance to the Bloom-Richardson grading system (Bloom and Richardson, 1957). Oestrogen and progesterone receptor status was established as described by the European Organization for Research and Treatment of Cancer (EORTC, 1980). With respect to treatment, 33 (19%) received no adjuvant treatment, 83 (47%) received tamoxifen, while 59 (33%) received chemotherapy with or without tamoxifen. This study has been approved by the Institutional Review Board of the University of Turin.

Table 1 Distribution of numerical variables in the study

| Variable                  | No. of patients | Mean±s.e.* | Median | Range   |
|---------------------------|-----------------|------------|--------|---------|
| KLK14 (arbitrary units)   | 178             | 136±22     | 4.28   | 0.00–1219 |
| Age (years)               | 175             | 57.5±0.98  | 58.0   | 25–87   |
| Tumour size (cm)          | 175             | 2.5±0.12   | 2.20   | 0.01–15.00 |
| Lymph nodes†              | 160             | 3.6±0.5    | 1      | 0–35    |

*SE, standard error. †Number of lymph nodes positive for malignancy.

Table 2 Associations between KLK14 status* and other variables in 178 patients with epithelial breast carcinomas

| Variable                  | Total KLK14-negative | KLK14-positive | P value |
|---------------------------|----------------------|----------------|---------|
| Age (years)               | 175                  |                |         |
| <45                       | 34                   | 22 (64.7)      | 12 (35.3) | 0.63† |
| 45–55                     | 46                   | 34 (73.9)      | 12 (26.1) |
| >55                       | 95                   | 64 (67.4)      | 31 (32.6) |
| X                         | 3                    |                |         |
| Sex                       | 175                  |                |         |
| Male                      | 92                   | 56 (60.4)      | 36 (39.6) |
| Female                    | 83                   | 64 (77.1)      | 19 (22.9) |
| Menopausal status         | 175                  |                |         |
| Pre/peri                  | 113                  | 76 (67.3)      | 37 (32.7) |
| Post                      | 62                   | 44 (71.0)      | 18 (29.0) | 0.73* |
| No. of patients (% )      |                      |                |         |

*KLK14 status a and other variables in 178 patients with epithelial breast carcinomas. X Status unknown.

ªCutoff point: 40.5, equals to 69th percentile. †Bloom-Scarff-Richardson grading system, ‡TNM system. ††x² test. †††Fisher’s Exact Test. X Status unknown.
Total RNA extraction and cDNA synthesis

Tumour tissues were minced with a scalpel, on dry ice, and transferred immediately to 2 ml polypropylene tubes. They were then homogenized and total RNA was extracted using Trizol™ reagent (Gibco – BRL) following the manufacturer’s instructions. The concentration and purity of mRNA were determined spectrophotometrically. Two µg of total RNA was reverse-transcribed into first-strand cDNA using the Superscript™ pre-amplification system (Gibco – BRL). The final volume was 20 µl.

Quantitative real-time polymerase chain reaction (PCR) and continuous monitoring of PCR products

Based on the published genomic sequence of KLK14 (GenBank accession #AF161221), two gene-specific primers were designed (6F5: 5’-AGT GGG TCA TCA CTG CTG CT-3’ and 6R8: 5’-TGCTTT CCT CAA TCC AGC TT-3’). These primers spanned more than two exons to avoid contamination by genomic DNA.

Real-time monitoring of PCR reaction was performed using the LightCycler™ system (Roche Molecular Systems, Indianapolis, IN, USA) and the SYBR green I dye, which binds preferentially to double-stranded DNA. Fluorescence signals are proportional to the concentration of the product and are measured at the end of each cycle and immediately displayed on a computer screen, permitting real time monitoring of the PCR reaction. The reaction is characterised at the point during cycling when amplification of PCR products is first detected, rather than the amount of PCR product accumulated after a fixed number of cycles. The higher the starting quantity of the template, the earlier a significant increase in fluorescence is observed. The threshold cycle is defined as the fractional cycle number at which fluorescence passes a fixed threshold above baseline.

Endogenous control

For each sample, the amount of KLK14 cDNA and of an endogenous control (β-actin, a housekeeping gene) were determined using a calibration curve (see below). The amount of KLK14 was then divided by the amount of the endogenous reference, to obtain a normalised KLK14 value.

Standard curve construction

The full-length mRNA sequence of the KLK14 gene was amplified by PCR using gene-specific primers, and the PCR product was cloned into a TOPO TA cloning vector (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. A plasmid containing β-actin cDNA, was similarly prepared. Plasmids were purified using a mini-prep kit (Qiagen Inc., Valencia, CA, USA). Different standard curves for actin and for KLK14 were constructed using serial dilutions of the plasmid. These standards were included in each run. The LightCycler software automatically calculates the standard curve by plotting the starting dilution of each standard sample vs the threshold cycle, and the sample concentrations are then calculated accordingly. Standards for both KLK14 and actin RNAs were defined to contain an arbitrary starting concentration, since no primary preparations exist. Hence, all calculated concentrations are relative to the concentration of the selected standard. Each sample was repeated twice to ensure reproducibility.

PCR amplification

The PCR reaction was carried out on the LightCycler™ system. For each run, a master mixture was prepared on ice, containing 1 µl of cDNA, 2 µl of LC DNA Master SYBR Green 1 mix, 50 ng of primers and 1.2 µl of 25 mM MgCl₂. After the reaction mixture was loaded into the glass capillary tube, the cycling conditions were carried out as shown in Table 3.

Melting curve

For distinguishing specific from non-specific products and primer dimers, a melting curve was obtained after amplification by holding the temperature at 70°C for 30 s followed by a gradual increase in temperature to 98°C at a rate of 0.2°C per s, with the signal acquisition mode set at step. To verify the melting curve results, representative samples of the PCR products were run on 1.5% agarose gels, purified, and cloned into the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The inserts were sequenced from both directions using vector-specific primers with an automated DNA sequencer.

Statistical analysis

Patients were subdivided into groups based on different clinical or pathologic parameters (Table 2) and statistical analyses were performed using SAS software (SAS Institute, Cary, NC, USA). An optimal cutoff value was defined by χ² analysis based on the ability of KLK14 values to predict the disease-free survival (DFS) and overall survival (OS) of the study population. According to this value, tumours were categorised as KLK14-positive or KLK14-negative and associations between KLK14 status and other qualitative variables were analysed using the χ² or the Fisher’s Exact test, where appropriate. The cutoff value for tumour size was 2 cm. Lymph node status was either positive (any positive number of nodes) or negative. Age was categorised into three groups: less than 45 years, 45–55 years and greater than 55 years. Survival analyses were performed by constructing Kaplan–Meier disease free survival (DFS) and overall survival (OS) curves and differences between curves were evaluated by the log-rank test (Mantel, 1966), as well as by estimating the relative risks for relapse and death using the Cox proportional hazards regression model (Cox, 1972). Cox analysis was conducted at both univariate and multivariate levels. Only patients for whom the status of all variables was known were included in the multivariate regression models, which incorporated KLK14 and all other variables for which the patients were characterised. The multivariate models were adjusted for KLK14 expression in tumours, patient age, tumour size, stage, grade, histologic type and oestrogen receptor (ER) and progesterin receptor (PR) status.

Table 3 Experimental protocol used for quantitative PCR amplification of the KLK14 gene

| Segment number | Temperature target (°C) | Hold time (s) | Slope (C/s) | Application mode |
|----------------|------------------------|--------------|-------------|-----------------|
| Program: Denaturation | 1 | 95 | 600 | 20 | None |
| Program: PCR | 1 | 95 | 0 | 20 | None |
| 2 | 62 | 5 | 20 | None |
| 3 | 72 | 40 | 20 | None |
| 4 | 85 | 5 | 20 | Single |
| Program: Melting | 1 | 95 | 0 | 20 | None |
| 2 | 72 | 30 | 20 | None |
| 3 | 97 | 0 | 0.2 | Step |
| Program: Cooling | 1 | 40 | 30 | 1 | None |
RESULTS

Relationship between KLK14 expression and other parameters

KLK14 mRNA levels ranged from 0 to 1219 arbitrary units in breast cancer tissues, with a mean ± s.e. of 136 ± 22. The cutoff point (40.5 arbitrary units; 69th percentile) indicated that 55 (31%) of the 178 breast tumour tissues were positive for KLK14 expression (Figure 1). Table 2 depicts the distribution of KLK14 expression, positive or negative, in breast tumour tissues in relation to other established prognostic factors such as menopausal status, tumour size, stage, grade, histological type, nodal status, steroid receptor status and adjuvant therapy. Patients with KLK14-positive breast tumours more frequently had advanced stage (III) disease (P=0.032). Significant associations between KLK14 expression and tumour size, grade and histology, or menopausal, nodal and steroid receptor status were not observed.

Univariate and multivariate survival analysis

The strength of association between each clinicopathological variable and DFS and OS is displayed in Table 4. In univariate analysis, patients with KLK14-positive tumours had a significantly increased risk of relapse (decreased DFS) and death (decreased OS) (hazards ratios of 2.31 and 2.21; P=0.001 and 0.005, respectively). Importantly, when treated as a continuous variable, KLK14 expression retained its statistically significant association with decreased DFS and OS (P<0.001). Further, when survival outcomes were adjusted for all other variables in the multivariate analysis (i.e. Cox proportional hazard regression model), the adverse effects of KLK14 positivity on DFS and OS were preserved (hazards ratios of 2.14 and 1.99; P=0.009 and 0.029, respectively), implying that KLK14 expression is an independent prognostic indicator.

Figure 1 Determination of the optimal cutoff value for KLK14 expression. For details, see text.

Table 4 Univariate and multivariate analysis of KLK14 expression in relation to DFS and OS

| KLK14 status       | Disease-free survival (DFS) | Overall survival (OS) |
|--------------------|-----------------------------|-----------------------|
|                    | HRa  | 95% CIb | P value | HRa  | 95% CIb | P value |
| Univariate analysis (n=164) |      |        |        |      |        |        |
| Categorical variablec |      |        |        |      |        |        |
| Negative           | 1.00 |        |        | 1.00 |        |        |
| Positive           | 2.31 | 1.39 – 3.85 | 0.001 | 2.21 | 1.27 – 3.83 | 0.005 |
| Continuous variable | 1.00 | 1.00 – 1.002 | <0.001 | 1.00 | 1.00 – 1.002 | <0.001 |
| Multivariate analysisd (n=148) |      |        |        |      |        |        |
| Categorical variablec |      |        |        |      |        |        |
| Negative           | 1.00 |        |        | 1.00 |        |        |
| Positive           | 2.14 | 1.21 – 3.80 | 0.009 | 1.99 | 1.07 – 3.70 | 0.029 |

aHazard ratio (HR) estimated from Cox proportional hazard regression model. bConfidence interval of the estimated HR. cKLK14 status based on a cutoff point equal to the 69th percentile of the distribution of KLK14 values. dMultivariate models were adjusted for lymph node status, tumour size, patient age, grade, histologic type, ER and PR expression.
KLK14 expression and breast cancer prognosis
GM Yousef et al

DISCUSSION

The optimal management of women with breast cancer involves a multidisciplinary approach, including the use of biological markers. Ultimately, the goal is to select the best marker or panel of markers that are most informative in terms of their ability to predict relapse, disease progression, survival and response to therapy. Traditional prognostic/predictive factors in breast cancer include tumour size, grade, nodal status, hormone receptor status, vascular invasion and age (Denley et al, 2001). However, only hormone receptor status has predictive value in selecting patients who are likely to respond to therapy, and is the only marker recommended for routine use by the American Society of Clinical Oncology (Smith et al, 2001) and the College of American Pathologists Consensus Statement (Fitzgibbons et al, 2000).

Many other potential biological markers have been identified as prognostic factors including p53, c-myc, BCL-2, HER-2, vascular endothelial growth factor (VEGF), urokinase plasminogen activator (uPA), CA 15-3, BR 27.29 and cathepsin B and D (Maguire et al, 1998; Duffy et al, 1999; Scorilas et al, 1999; Hamilton and Piccart, 2000; Bundred, 2001). Some markers are also predictive. For instance, expression of HER-2 has value in determining response to treatment and in selecting patients for Herceptin therapy (Ross and Fletcher, 1998). The multitude of new candidate biomarkers will likely lead to insights into the cellular changes that correlate with, or determine the different biological properties and diverse behaviour of individual breast tumours. Furthermore, stratifying patients based on the presence or absence of such markers may help to tailor different therapeutic strategies to meet individual needs (Clark et al, 1994).

Table 5 Associations between KLK14 and DFS and OS in subgroups of patients stratified by tumour size, nodal status, oestrogen and progesterone receptor status

| Variable                  | Disease-free survival (DFS) | Overall survival (OS) |
|---------------------------|-----------------------------|-----------------------|
|                           | HR*                        | 95% CI*               | P value   | HR*                       | 95% CI*               | P value   |
| Tumor size ≤2cm (n=79)    |                             |                       |           |                           |                       |           |
| KLK14 unadjusted          | 3.48                        | 1.47–8.29             | 0.004     | 4.13                      | 1.47–11.64            | 0.007     |
| KLK14 adjusted            | 3.52                        | 1.22–11.31            | 0.021     | 6.26                      | 1.46–26.87            | 0.014     |
| Tumor size >2cm (n=85)    |                             |                       |           |                           |                       |           |
| KLK14 unadjusted          | 1.66                        | 0.88–3.13             | 0.11      | 1.51                      | 0.77–2.92             | 0.22      |
| KLK14 adjusted            | 1.58                        | 0.77–4.09             | 0.17      | 1.90                      | 0.84–4.27             | 0.12      |
| Node negative (n=65)      |                             |                       |           |                           |                       |           |
| KLK14 unadjusted          | 2.27                        | 0.64–8.06             | 0.20      | 1.51                      | 0.27–8.24             | 0.63      |
| KLK14 adjusted            | 2.01                        | 0.46–8.71             | 0.35      | 1.89                      | 0.29–12.15            | 0.49      |
| Node positive (n=88)      |                             |                       |           |                           |                       |           |
| KLK14 unadjusted          | 2.24                        | 1.24–4.06             | 0.007     | 2.12                      | 1.14–3.95             | 0.017     |
| KLK14 adjusted            | 2.31                        | 1.21–4.34             | 0.010     | 2.13                      | 1.09–4.14             | 0.025     |
| ER negative (n=59)        |                             |                       |           |                           |                       |           |
| KLK14 unadjusted          | 1.83                        | 0.84–3.98             | 0.12      | 1.97                      | 0.90–4.33             | 0.087     |
| KLK14 adjusted            | 0.89                        | 0.33–2.34             | 0.82      | 0.92                      | 0.33–2.52             | 0.88      |
| ER positive (n=99)        |                             |                       |           |                           |                       |           |
| KLK14 unadjusted          | 3.40                        | 1.65–6.99             | 0.001     | 3.47                      | 1.49–8.05             | 0.004     |
| KLK14 adjusted            | 3.14                        | 1.26–7.79             | 0.014     | 2.88                      | 1.01–8.18             | 0.047     |
| PR negative (n=72)        |                             |                       |           |                           |                       |           |
| KLK14 unadjusted          | 1.68                        | 0.85–3.34             | 0.13      | 1.83                      | 0.91–3.69             | 0.088     |
| KLK14 adjusted            | 1.27                        | 0.59–2.74             | 0.53      | 1.31                      | 0.06–2.89             | 0.49      |
| PR positive (n=87)        |                             |                       |           |                           |                       |           |
| KLK14 unadjusted          | 3.61                        | 1.63–7.97             | 0.001     | 3.17                      | 1.25–8.06             | 0.014     |
| KLK14 adjusted            | 6.04                        | 2.19–16.61            | 0.001     | 4.45                      | 1.37–14.39            | 0.012     |

*Hazard ratio (HR) estimated from Cox proportional hazard regression model. **Confidence interval of the estimated HR. **Multivariate models were adjusted for tumour grade, nodal status, ER, PR, histologic type and age. **Multivariate models were adjusted for tumour size, grade, ER, PR, histologic type and age. **Multivariate models were adjusted for tumour size, grade, nodal status, ER, histologic type and age.
In this paper, we identify KLK14 as a new independent marker of unfavourable prognosis in breast cancer. Patients with KLK14-positive breast tumours were more likely to have advanced stage (III) disease. When assessing KLK14 expression in terms of predicting survival outcomes, we found an increased risk of relapse and death for patients with KLK14-positive tumours. This was also observed in subsets of patients with a tumour size ≤2 cm, positive nodal, OR and PR status. Hence, KLK14 expression may aid in predicting relapse, disease progression and/or survival in breast cancer patients.

Interestingly, the results obtained for KLK14 in this study are comparable to those obtained for KLK3, KLK6 and KLK15 in breast cancer (Yu et al, 1995; Anisowicz et al, 1996) and KLK4, KLK5 and KLK10 in ovarian cancer (Kim et al, 2001; Luo et al, 2001b; Obiezu et al, 2001), in that high expression of these kallikrein genes also correlates with patient prognosis. Similar to KLK14, these genes are also under steroid hormone regulation (Yousef and Diamandis, 2001). These observations allow us to speculate that multiple kallikreins may participate in a common enzymatic pathway that plays a role in the normal physiology of the breast. This pathway may be deregulated in breast carcinogenesis. As is the case with many other serine proteases, certain kallikreins may degrade the extracellular matrix promoting tumour invasiveness and metastasis.

It was recently realised that KLK14 is under steroid hormone regulation, particularly androgens and progestins, and that these effects are mediated through the androgen receptor (our unpublished data). It is also known that breast cancer is a hormone-dependent malignancy (Russo and Russo, 1998) and that androgen receptors are present in 70–90% of primary breast tumours (Soreide et al, 1992), and 75% of breast cancer metastases (Lea et al, 1989). Thus, it is likely that the androgen receptor, acting as a ligand-activated transcription factor, upregulates KLK14 gene expression during breast carcinogenesis.

The role of androgens in the aetiology of breast cancer is ill-defined. In vitro, they both stimulate (MCF-7, MDA-453) or inhibit (T-47D, ZR-75-1, MFM-223) the growth of AR-positive breast cancer cell lines (Hackenberg et al, 1991; Birrell et al, 1995). Animal studies have demonstrated that androgens shorten the latency period, enhance tumour size and increase the incidence of breast tumours, by promoting rather than initiating carcinogenesis in rodents (Liao et al, 1998; Xie et al, 1999). These effects may be mediated by androgen-regulated genes that directly function in cell growth regulation and through interaction of the AR with other transcription regulators, allowing for cross-talk with other growth pathways (Brys, 2000). Thus, the identification of androgen regulated genes, such as KLK14, may help to define new targets for breast cancer treatment. Such new treatments may be particularly important in metastatic disease, where the AR is often the sole steroid receptor expressed.

In summary, we quantified KLK14 expression in breast tumours and found that high KLK14 expression is associated with decreased DFS and OS in both univariate and multivariate analysis. Additional basic and clinical studies are required to delineate the activity of KLK14 in both the normal and malignant breast and to further define the clinical value of this biomarker.

REFERENCES

Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R (1996) A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 2: 624–636
Barr JJ (2001) Clinical practice. Prostate-specific-antigen testing for early prostate cancer. N Engl J Med 344: 1373–1377
Birrell SN, Bentel JM, Hickey TE, Ricciardielli C, Weger MA, Horsfall DJ, Tilley WD (1995) Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 52: 459–467
Bloom HG, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 10: 359–377
Brys M (2000) Androgens and androgen receptor: do they play a role in breast cancer? Med Sci Monit 6: 433–438
Bundred NJ (2001) Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27: 137–142
Clark GM, Hilsenbeck SG, Ravdin PM, De Laurentiis M, Osborne CK (1994) Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat 32: 105–112
Cox DR (1972) Regression models and life tables. R Stat Soc B 34: 187–202
Diamandis EP, Okui A, Mituil S, Luo YQ, Sosaipillai A, Grass L, Nakamura T, Howarth DJ, Yamaguchi N (2002) Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 62: 295–300
Diamandis EP, Yousef GM (2001) Human tissue kallikrein gene family: a rich source of novel disease biomarkers. Expert Rev Mol Diagn 1: 182–190
Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Eglrud T, Nelson PS, Shiosaka A, Little S, Lilja H, Stenman UH, Rittenhouse HG, Wain H (2000a) New nomenclature for the human tissue kallikrein gene family. Clin Chem 46: 1855–1858
Diamandis EP, Yousef GM, Luo YQ, Magklara A, Obiezu CV (2000b) The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 11: 54–60
Diamandis EP, Yousef GM, Sosaipillai AR, Bunting P (2000c) Human kallikrein 6 (zyme/protease M/nerolin): a new serum biomarker of ovarian carcinoma. Clin Biochem 33: 579–583
Duffy MJ (2001) Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 34: 347–352
Duffy MJ, Maguire TM, McDermott EW, O’Higgins N (1999) Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71: 130–135
EORTC (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second EORTC Workshop, held on 16–17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer 16: 1513–1515
Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley P, Simpson JF, Connolly IL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 966–978
Gottesman M (1990) The role of proteases in cancer. Semin Cancer Biol B: 97–160
Hackenberg R, Luttchesen S, Hofmann K, Kunzmann R, Holzel F, Schulz KD (1991) Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Res 51: 5722–5727
Hamilton A, Piccart M (2000) The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and B-cell-2. Ann Oncol 11: 647–663
Herzennyl LI, Pilebani M, Carraro P, De Paoli M, Roveroni G, Cardin R, Tulasay Z, Naccarato R, Farinati F (1999) The role of cytokine and serine proteases in colorectal cancer. Cancer 86: 1135–1142
Hooper JD, Bui LT, Rae FK, Harvey TJ, Myers SA, Ashworth LK, Clements JA (2001) Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics 73: 117–122
Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52: 23–47
Kim H, Scrilias A, Katsaros D, Yousef GM, Massobrio M, Fracchioli S, Piccimino R, Gordini G, Diamandis EP (2001) Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 84: 643–650
Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Spathe K, Dettmar P, Hoffer H, Janicke F, Schmitt M, Graeff H (1999) Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79: 1746–1751

Lea OA, Kvinnslens S, Thorsen T (1989) Improved measurement of androgen receptors in human breast cancer. Cancer Res 49: 7162–7167

Liao DZ, Fantazis CG, Hou X, Li SA (1998) Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: probable mediation by steroid receptors. Carcinogenesis 19: 2173–2180

Luo LY, Bunting P, Scorilas A, Diamandis EP (2001a) Human kallikrein 10: a new tumor marker for ovarian carcinoma? Clin Chim Acta 306: 111–118

Luo LY, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, Rigault de la Longrais IA, Howarth DJ, Diamandis EP (2001b) Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 7: 2372–2379

Luo LY, Raipert-De Meyts ER, Jung K, Diamandis EP (2001c) Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumor suppressor gene in normal and malignant testicular tissue. Br J Cancer 85: 220–224

Magklara A, Scorilas A, Catalona WJ, Diamandis EP (1999) The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 45: 1960–1966

Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP (2001) The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 7: 806–811

Maguire TM, Shering SG, Duggan CM, McDermott EW, O’Higgins NJ, Duffy MJ (1998) High levels of cathepsin B predict poor outcome in patients with breast cancer. Int J Biol Markers 13: 139–144

Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170

Obiezu CV, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Rigault de la Longrais IA, Arisio R, Diamandis EP (2001) Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 7: 2380–2386

Parkin DM, Pisani P, Ferlay J (1999) estmates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827–841

Peto R, Boreham J, Clarke M, Davies C, Beral V (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 355: 1822

Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW (1998) Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 35: 275–368

Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive Factor, and target for therapy. Oncologist 3: 237–252

Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3: 49–61

Scorilas A, Yotis I, Pateras C, Trangas T, Talieri M (1999) Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clin Cancer Res 5: 815–821

Smith RA, Von Eschenbach AC, Wender A, Levin B, Byers T, Rothenberger D, Brooks D, Cressman W, Cohen C, Runowicz C, Salsow D, Cokkinides V, Eyer H (2001) American Cancer Society guidelines for early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers, and update 2001: testing for early lung cancer detection. CA Cancer J Clin 51: 7–38

Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnslens S (1992) Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18: 112–118

Xie B, Tsao SW, Wong YC (1999) Sex hormone-induced mammalian carciino genesis in female noble rats: the role of androgens. Carcinogenesis 20: 1597–1606

Yousef GM, Chang A, Diamandis EP (2000a) Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem 275: 11891–11898

Yousef GM, Chang A, Scorilas A, Diamandis EP (2000b) Genomic organization of the human kallikrein gene family on chromosome 19q13.3–13.4. Biochem Biophys Res Commun 276: 125–133

Yousef GM, Magklara A, Diamandis EP (2000c) KLK12 is a novel serine protease and a new member of the human kallikrein gene family – differential expression in breast cancer. Genomics 69: 331–341

Yousef GM, Diamandis EP (2001) The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 22: 184–204

Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiard G, Massobrio M, Diamandis EP, Katsaros D (2001a) Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res 61: 7811–7818

Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP (2001b) Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res 61: 3425–3431

Yousef GM, Scorilas A, Jung K, Ashworth LK, Diamandis EP (2001c) Molecular cloning of the human kallikrein 13 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem 276: 53–61

Yousef GM, Diamandis EP (2002) Human kallikreins: common structural features, sequence analysis and evolution. Curr Genom In Press

Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJ, Levesque MA, Roagna R, Ponzonze R, Sismondi P (1995) Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104–2110